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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.015The expression of neurotensin (NT) and its receptor (NTR1) is up-regulated in experimental colitis
and inﬂammatory bowel disease; NT/NTR1 interactions regulate gut inﬂammation. During active
inﬂammation, metabolic shifts toward hypoxia lead to the activation of hypoxia-inducible factor
(HIF)-1, which enhances vascular endothelial growth factor (VEGF) expression, promoting angio-
genesis. We hypothesized that NT/NTR1 signaling regulates intestinal manifestations of hypoxia
and angiogenesis by promoting HIF-1 transcriptional activity and VEGFa expression in experi-
mental colitis. We studied NTR1 signaling in colitis-associated angiogenesis using 2,4,6-
trinitrobenzenesulfonic acidetreated wild-type and NTR1-knockout mice. The effects of NT on
HIF-1a and VEGFa were assessed on human colonic epithelial cells overexpressing NTR1 (NCM460-
NTR1) and human intestinal microvascular-endothelial cells. NTR1-knockout mice had reduced
microvascular density and mucosal integrity score compared with wild-type mice after 2,4,6-
trinitrobenzenesulfonic acid treatment. VEGFa mRNA levels were increased in NCM460-NTR1 cells
treated with 107 mol/L NT, at 1 and 6 hours post-treatment. NT exposure in NCM460-NTR1 cells
caused stabilization, nuclear translocation, and transcriptional activity of HIF-1a in a diac-
ylglycerol kinaseedependent manner. NT did not stimulate tube formation in isolated human in-
testinal macrovascular endothelial cells but did so in human intestinal macrovascular endothelial
cells cocultured with NCM460-NTR1 cells. Our results demonstrate the importance of an NTR1eHIF-
1aeVEGFa axis in intestinal angiogenic responses and in the pathophysiology of colitis and in-
ﬂammatory bowel disease. (Am J Pathol 2014, 184: 3405e3414; http://dx.doi.org/10.1016/
j.ajpath.2014.08.015)Supported by grants from the NIH (DK60729, 1P50 DK64539, and DK
47373 to C.P.; DK50984 and DK69854 to C.F.), a fellowship grant award
from the Crohn’s and Colitis Foundation of America, Inc. (K.B.), the Blinder
Research Foundation for Crohn’s Disease (I.K.M.L.), and the Morphology
and Cell Imaging Core of the CURE Center (CURE:DDRCC DK41301).
Disclosures: None declared.The term inﬂammatory bowel disease (IBD) is used to
describe two chronic and debilitating inﬂammatory disorders,
namely, Crohn disease (CD) and ulcerative colitis. Although
genetic and environmental factors and microbes are involved
in the development of both diseases,1 the etiology of IBD stillstigative Pathology.
.
Bakirtzi et alremains largely unclear. The neuropeptide neurotensin (NT),
via its high-afﬁnity receptor, NTR1, is an important mediator
of intestinal inﬂammation.2,3 NT, a 13eamino acid neuro-
peptide initially isolated from bovine hypothalamus,4 is
expressed in the brain and the intestine.5 In the intestine, NT is
expressed in the endocrine N cells, localized in the intestinal
mucosa.6 Expression levels of NT and NTR1 are up-regulated
in the inﬂamed colonic mucosa in animal models and IBD
patients.2,3,7 Moreover, evidence from our and other labora-
tories suggests that NT/NTR-1 signaling is implicated in the
pathophysiology of colitis by mechanisms involving the
regulation of gene expression of inﬂammation-associated
genes.7e11
It is well established that, during active inﬂammation such
as IBD, there are severe metabolic shifts toward hypoxia,12e14
leading to the activation of the transcription factor hypoxia-
inducible factors (HIF) 1 and 2.15,16 For example, surgical
specimens of inﬂamed intestine contain elevated levels of HIF-
1a and HIF-2a.17 Under normoxic conditions, HIF-1a is
targeted for proteasomal degradation.18,19 HIF-1, as a key
regulator of the physiological and pathophysiological re-
sponses to hypoxia, induces the expression of a broad genetic
program, including angiogenic genes such as vascular endo-
thelial growth factor (VEGF),20,21 by binding on the appro-
priate HIF-responsive elements (HREs) present on their
promoter region. VEGFa is a major paracrine growth factor
involved in blood vessel development as well as endothelial
cell proliferation and migration, playing a central role in
angiogenesis and neovascularization.22 Therefore, the regula-
tion of HIF-1 is important for the reconstitution of the vascu-
lature at sites of intestinal injury and inﬂammation. Several
pro-inﬂammatory cytokines are able to activate HIF-1 in
selected cell types in culture,23e25 whereas increased HIF
signaling in mouse colon epithelium results in exacerbated
colitis in vivo.26
Little is known about the ability of NT to modulate angio-
genesis and neovascularization, whereas there is no evidence
of a role for NT in these responses in the intestinal tract. NT
and its analogue, TJN-950, induce neovascularization in the rat
cornea in vivo.27 Moreover, liver tumoreinitiating cells pro-
mote tumor angiogenesis via an NT/IL-8/CXCL1 signaling
mechanism.28 We hypothesized that NT/NTR1 signaling
promotes HIF-1 transcriptional activity in the inﬂamed gut,
causing an increase in VEGFa expression, which may then
play a role in intestinal manifestations of hypoxia and
angiogenesis.
We show here that, during colitis, NTR1-deﬁcient mice
have reduced angiogenesis. We also show that NT/NTR1
signaling in human colonocytes induces HIF-1 activity in a
diacylglycerol kinase (DGK)-dependent manner,29,30 causing
increased expression of its downstream target VEGFa, which
in turn triggers tube formation in human intestinal microvas-
cular endothelial cells (HIMECs).We demonstrate, for the ﬁrst
time to our knowledge, that neuropeptide signaling can regu-
late the effects of the transcription factor HIF-1a, an event
linked to NT-associated angiogenesis. Our results collectively3406demonstrate the importance of NTR1eHIF-1aeVEGFa in-
teractions in the pathophysiology of colitis and the intestinal
angiogenic response.
Materials and Methods
Antibodies and Reagents
We used the following antibodies and reagents: antieHIF-1a
polyclonal antibody (1:500, ab2185; Abcam plc, Cambridge,
UK), b-actin monoclonal antibody (1:1000, 130065; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), b-tubulin poly-
clonal antibody (1:1000, PA1-41331; Thermo Fischer Sci-
entiﬁc Inc., Rockford, IL), NT (048-03; Phoenix
Biotechnology, Inc., San Antonio, TX), NTR-1 inhibitor SR-
48692 (3721; Tocris Bioscience, Bristol, UK), HIF-1a in-
hibitor PX-478 (202350; MedKoo Biosciences, Inc., Chapel
Hill, NC), DGK inhibitor II (266788; Calbiochem-
Novabiochem Corp., San Diego, CA), VEGFa inhibitor
CBO-P11 (676496; EMD Millipore, Billerica, MA), and
basic ﬁbroblast growth factor (13256-029; Life Technologies
Corp, Carlsbad, CA).
Transduction of NCM460 Cell Line with NTR1
The human neurotensin receptor 1 gene (NTSR1) was isolated
from pCR2.131 with EcoRV and inserted into lentiviral
backbone CMV-IRES-GFP-PGK-Puro (cytomegalovirus, in-
ternal ribosome entry site, green ﬂuorescent protein, phos-
phoglycerate kinase, puromycin resistance gene) at the EcoRV
site, 50 to internal ribosome entry site. Lentiviral particles
expressing NTRS1 were generated by transient cotransfection
of 293T cells with a three-plasmid combination, as previously
described.32 After transduction, NCM460-NTR1 cells were
maintained as described below in Cell Cultures.
Cell Cultures
Human colonic epithelial cells (NCM460-NTR1) were
cultivated in M3D medium (Incell Corporation, LLC, San
Antonio, TX) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 1% L-glutamine, 10 U/mL
penicillin, and 100 mg/mL streptomycin at 37C in air
supplemented with 5% CO2. Where indicated, cells were
treated with 107 mol/L NT (30 minutes or 6 hours), in the
presence of 7  107 VEGFa inhibitor CBO-P11, 30 mi-
nutes of pretreatment with 107 mol/L NTR1 antagonist
SR-48692, 30 minutes of pretreatment with 3 106 mol/L
DGK inhibitor II, or 18 hours of pretreatment with
40  106 mol/L HIF-1a inhibitor PX-478. Fractionation
into cytoplasmic and nuclear preparations was performed
where indicated using the Nuclei EZ Prep nuclear isolation
kit (Sigma-Aldrich, St. Louis, MO).
HIMECs were isolated as previously described.33 Brieﬂy,
HIMECs were obtained from normal areas of the intestine
from patients admitted for bowel resection. HIMECs wereajp.amjpathol.org - The American Journal of Pathology
NTeHIF-1aeVEGFa in Colonic Inﬂammationisolated by enzymatic digestion and subsequently cultured in
MCDB131 medium (Sigma-Aldrich) supplemented with 20%
fetal bovine serum (BioWhittaker, Inc., Walkersville, MD),
antibiotics (BioWhittaker), heparin (Sigma-Aldrich), and
endothelial cell growth factor (Hybridoma Core Facility,
Cleveland, OH). Cultures of HIMECswere maintained at 37C
in 5% CO2. HIMECs were used between passages 7 and 12.
Gel Electrophoresis and Immunoblot Analysis
Protein samples were subjected to sodium dodecyl sulfa-
teepolyacrylamide gel electrophoresis according to
Laemmli34 and were transferred to polyvinylidene diﬂuor-
ide membranes in 25 mmol/L Tris, 192 mmol/L glycine.
Membranes were blocked (phosphate-buffered saline, 10%
nonfat dry milk, 0.05% Tween 20) and probed with anti-
bodies, followed by corresponding horseradish perox-
idaseelabeled secondary antibodies (1:1000). Blots were
developed with enhanced chemiluminescence reagent
(PerkinElmer Inc., Waltham,MA).Western blot bands were
quantiﬁed using the LAS-4000 mini image analyzer (Fuji-
ﬁlm Medical Systems USA, Inc., Stamford, CT). Data are
represented by cropped images from the original mem-
branes. Loading controls (b-actin or b-tubulin) were derived
from the same original membranes.
Luciferase Assays Using Reporters Based on HRE
Promoter Fragments
NCM460-NTR1 cells were transfected using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) with HRE-luciferase, a pGL2
vector containing three hypoxia response elements from the
Pgk-1 gene upstream of ﬁreﬂy luciferase (26731; Addgene,
Inc., Cambridge, MA). Thymidine kinase (TK)-Renilla lucif-
erase was cotransfected to control for transfection efﬁciency.
Forty-eight hours after transfection, cells were pretreated with
3  106 mol/L DGK inhibitor II (30 minutes), followed by
107 mol/L NT, and cell extracts were prepared for luciferase
activity to be measured using the Dual Luciferase Reporter
Assay System (Promega Corp., Madison, WI).
Enzyme-Linked Immunosorbent Assay
Immunoassays of NCM460-NTR1 cell levels of VEGFa
and HIF-1a (DY293B-05 and DYC1935-5, respectively;
R&D Systems Inc., Minneapolis, MN) were performed ac-
cording to the manufacturer’s instructions.
Tube-Formation Assay
HIMECs (4  104 cells/well) were plated on 400 mL of
Matrigel-coated (BD Biosciences, San Jose, CA), 24-well
plate and supplemented with complete MCDB131 medium.
In coculture experiments, NCM460-NTR1 1  103 cells per
well was added to the HIMEC cultures. HIMECs or HIMEC/
NCM460-NTR1 cocultures were serum-starved for 2 hoursThe American Journal of Pathology - ajp.amjpathol.organd then supplemented with M3D/MCDB131 medium mix
(supplemented as indicated with 107 mol/L NT and/or
7  107 mol/L VEGF inhibitor CBO-P11). After 6 hours,
cells were labeled with calcein (Life Technologies, Grand Is-
land, NY) for 30 minutes according to the manufacturer’s in-
structions and were visualized under a Leica DMI6000
microscope (Leica Microsystems Wetzlar GmbH, Wetzlar,
Germany). Images were captured with an Orca-R2 ER-150
CCD camera (Hamamatsu Photonics K.K., Bridgewater, NJ)
and processed with Photoshop CS5 version 12 (Adobe Sys-
tems Inc., San Jose, CA), as previously described.35 Relative
total tube length present in each entireﬁeld (pixels/pixels2) was
measured using ImageJ version 1.46d (NIH, Bethesda, MD).
Colitis Mouse Model
Animal studies were approved by the institutional AnimalCare
and Use Committee. Animals were maintained at the UCLA
Animal Research Facility and received standard pelleted chow
and water ad libitum. 2,4,6-Trinitrobenzenesulfonic acid
(TNBS) colitis was induced as previously described36 in 8- to
12-week-old male homozygous NTR1-deﬁcient (NTR1-KO)
mice and control littermates (n Z 8 per group) by 100-mL
intracolonic injection of 250 mg/kg TNBS (Fluka Chemical
Corp., Ronkonkoma, NY). Control groups were injected with
100 mL of 30% ethanol intracolonically. Mice were returned to
their cages and sacriﬁced 48 hours post colitis induction by
carbon dioxide. Mice that received intracolonic administration
of 300 mg/kg NT (twice a day for 4 days post colitis induction)
were sacriﬁced 6 days after colitis induction. Colon tissues
were isolated and dissected for further analysis.
Quantitative RT-PCR
Total RNA from mouse or human colons was isolated using
standard TRIzol reagent protocol (Life Technologies), and
cDNA was prepared using the miRCURY LNA Universal
RT miRNA PCR cDNA kit (Exiqon, Woburn, MA).
Quantitative RT-PCR (qPCR) for mRNAs of interest was
performed using the speciﬁc primers obtained (Applied
Biosystems Inc., Foster City, CA) according to the manu-
facturer’s instructions.
IHC Analysis
Colon tissues were ﬁxed in 4% paraformaldehyde and
embedded in parafﬁn. Tissue sections were prepared by the
Translational Pathology Core Laboratory (UCLA). Sec-
tions were blocked and incubated with either rabbit poly-
clonal von Willebrand Factor (vWF) antibody (AB7356;
EMD Millipore) or mouse monoclonal CD-31 antibody
(550274; BD Pharmingen; BD Biosciences, San Jose, CA)
overnight at 4C. After washing, sections were incubated
with donkey anti-rabbit IgG, and slides were stained with an
ABC kit for color development (sc-2018; Santa Cruz
Biotechnology, Inc.). Sections were photographed under3407
Figure 1 NTR1-KO mice or WT littermates
received (or did not receive) intracolonic enema of
TNBS (250 mg/kg). Forty-eight hours later. mice
were sacriﬁced; colon tissues were collected, ﬁxed
in formalin, and embedded in parafﬁn; and endo-
thelial cells were stainedwith vonWillebrand factor
(vWF) antibody or CD31 antibody. A: Representa-
tive microphotographs of vWF- and CD31-stained
colon tissues. B: Relative vWFþ cells (endothelial
cells/mm2) in colon tissues. C: Relative CD31þ cells
(endothelial cells/mm2) in colon tissues. Compari-
son between mucosal integrity (D) and neutrophil
inﬁltration scores40 (E) given for TNBS-treated
NTR1-KO mice or WT littermates. Results are repre-
sentative or two separate experiments. Data are
expressed as means SEM (BeE). nZ 8 mice per
group. *P < 0.05, **P < 0.01, and ***P < 0.001
(Student’s t-test). Original magniﬁcation, 5 (A).
Bakirtzi et althe microscope, and computerized vWF-stained or CD-
31estained image analysis was performed using the Scion
Image Software (Scion Corp., Frederick, MD) as previously
described.37e39
Histological Scoring
Colon tissues of mice were sectioned and stained with he-
matoxylin and eosin. Microphotographs (original magniﬁ-
cation, 20) were recorded at multiple locations of colons
and analyzed in a blinded manner (K.B., I.K.M.L.), with
specimens scored on a scale of 0 to 6 for mucosal integrity,
0 to 3 for neutrophil inﬁltration, and 0 to 1 for mucosal
edema, according to a previously described scoring system
for acute colitis.40
Results
NT/NTR1 Signaling Is Required for Colitis-Associated
Neovascularization
It has been previously shown that angiogenesis is an integral
component of IBD pathogenesis, with vascular density being3408increased in the intestine of IBD patients.37,41 NT signaling
has been connected to tumor angiogenesis in the liver via NT/
IL-8/CXCL1 signaling pathway.28 To assess the potential
signiﬁcance of NT/NTR1 signaling in IBD with regard to
angiogenesis, we compared the vascular density betweenWT
and NTR1-KO mice after 2 days’ treatment with TNBS.
Immunohistochemistry analysis using an anti-vWF antibody
showed that while colonic angiogenesis was increased
signiﬁcantly in TNBS-treated WT mice compared with that
in untreated animals (PZ 0.0055), TNBS-treated NTR1-KO
mice showed signiﬁcantly less vWF-positive cells
(PZ 0.0007), at levels comparable to untreated NTR1-KO
controls (Figure 1, A and B). To verify the increased
angiogenic response after 2 days of TNBS-induced colitis,
we also performed immunohistochemistry analysis using an
antieCD-31 antibody and found increased CD-31epositive
cells in the colonic mucosa of TNBS-exposed versus control
mice (P Z 0.02785) (Figure 1, A and C). Moreover, histo-
logical scoring of TNBS-treated mice showed that TNBS-
associated mucosal integrity score was signiﬁcantly
improved in NTR1-KO mice compared with that in TNBS-
exposed WT mice (P Z 0.0334) (Figure 1D). Neutrophil
inﬁltration was increased in the TNBS-exposed colon of WTajp.amjpathol.org - The American Journal of Pathology
Figure 2 A: NT/NTR1 signaling promotes the
expression of VEGF. NCM460-NTR1 cells were
treated as indicated with 107-mol/L NT. VEGF
mRNA levels were assessed by qPCR. Results are
representative of two separate experiments. B:
VEGF protein levels were assessed at indicated time
points by enzyme-linked immunosorbent assay. C:
NTR1-KO mice or WT littermates received as indi-
cated intracolonic enema of TNBS (250 mg/kg).
Forty-eight hours later, mice were sacriﬁced and
colon tissues were collected for RNA isolation. The
levels of VEGFa expression were detected by qPCR.
Results are representative of two separate experi-
ments. D: C57BL6J mice received intracolonic
enema of 250 mg/kg TNBS, and 48 hours later mice
received intracolonic enema of 300 mg/kg NT twice
a day (8 hours apart) for the following 4 days. Mice
were sacriﬁced on the 6th day, colon tissues were
isolated, and VEGF mRNA levels in colon samples
were assessed by qPCR. Results are representative
of two separate experiments. Data are expressed as
means  SEM. n Z 3 (A); n Z 6 (B); n Z 8 per
group (C and D). *P < 0.05, **P < 0.01, and
***P < 0.001 (Student’s t-test).
NTeHIF-1aeVEGFa in Colonic Inﬂammationmice, with numerically lower levels in NTR1-KO mice, but
the results did not reach statistical signiﬁcance (Figure 1E).
These results suggest that NTR1 is important for colitis
outcome, consistent with ﬁndings from a prior study using
a different colitis model,42 and that it is required for
inﬂammation-driven angiogenesis.
NT Stimulates VEGFa Expression in Vitro and in Vivo
NT and its cognate receptor, NTR1, are involved in
intestinal inﬂammation and experimental colitis.2,3,42
The results shown in Figure 1, A and B also indicate
that NT/NTR1 activation is involved in colitis-associated
angiogenesis. Since VEGFa is a major angiogenic factor
linking angiogenesis and IBD pathogenesis,43 we exam-
ined the association of NTR1 signaling with VEGFa
expression. Human colonic epithelial cells stably
expressing NTR1 (NCM460-NTR1) were exposed to
107 mol/L NT, total RNA was isolated, and qPCR was
performed to assess VEGFa levels of expression. We
found that VEGFa expression was signiﬁcantly increased
at 1 and 6 hours after NT treatment (P < 0.0001 and
PZ 0.0082, respectively), whereas after 12 and 18 hours’
incubation, VEGFa levels were statistically indistin-
guishable from controls (Figure 2A). We further exam-
ined the protein level of VEGF using enzyme-linked
immunosorbent assay and found signiﬁcantly increasedThe American Journal of Pathology - ajp.amjpathol.orgVEGF expression in NCM460-NTR1 cell lysates after 1
and 6 hours of treatment with 107 mol/L NT (P < 0.0001
and PZ 0.0176, respectively) (Figure 2B). These results
indicate that NT/NTR1 signaling increases VEGF at both
the transcriptional and the translational levels.
Increased VEGFa mRNA Expression during TNBS-
Induced Colitis Is NTR1 Dependent
To conﬁrm the in vivo signiﬁcance of NTR1-induced VEGFa
mRNA expression in NCM460-NTR1 cells, we compared
VEGFa mRNA levels between WT and NTR1-KO mice
after 2 days of intracolonic TNBS exposure. Real-time PCR
showed that, compared with vehicle administration, colonic
VEGFa mRNA levels were increased in response to TNBS
administration in WT mice (P Z 0.0131) (Figure 2C).
Interestingly, TNBS-treated NTR1-KO mice showed no
signiﬁcant increase in VEGFa mRNA levels compared with
vehicle-treated NTR1-KO animals and had signiﬁcantly
lower VEGFa levels compared with TNBS-treated WT mice
(PZ 0.0423). On the other hand, the signiﬁcant increase in
vWF staining in TNBS-treated mouse colons compared with
controls (P Z 0.0375) was further increased after intra-
colonic administration of NT (P Z 0.0273 versus controls
and P Z 0.0419 versus TNBS-treated colons) (Figure 2D).
These data collectively suggest that NT/NTR1 signaling has
a role in colitis-induced angiogenesis.3409
Figure 3 NT promotes HIF-1a protein stabili-
zation. NCM460-NTR1 cells were treated as indi-
cated with 107-mol/L NT. A: HIF-1a mRNA levels
were assessed by qPCR. HIF-1a protein levels were
assessed by Western blot analysis (B) and band
densitometry (C). D: NCM460-NTR1 cells were
pretreated as indicated with 107 mol/L NTR1 in-
hibitor SR48692 (30 minutes) and/or 107 mol/L
NT, and HIF-1a protein levels were assessed using
WB analysis and band densitometry (E). F:
NCM460-NTR1 cells were treated with 107 mol/L
NT for 1 hour, stimulus was removed by switching
to complete media without NT, and HIF-1a protein
levels were assessed at indicated time points by
enzyme-linked immunosorbent assay. Results are
representative of two separate experiments. Data
are expressed as means  SEM. nZ 3. *P < 0.05,
**P < 0.01, and ***P < 0.001 (Student’s t-test).
Bakirtzi et alNT Signaling Promotes HIF-1a Stabilization in
NCM460-NTR1 Cells
Active inﬂammation such as IBD is characterized by
metabolic shifts toward hypoxia.12e14 Under these condi-
tions, the HIF, a transcription factor promoting VEGFa
expression,20,21 is activated. We therefore hypothesized that
the induction of VEGFa expression in NCM460-NTR1
cells after NT treatment involves NTR1-induced HIF-1a
activation. To address this hypothesis, NCM460-NTR1 cells
were treated with 107 mol/L NT for 30 minutes or 6 hours,
and total cell lysates were collected for mRNA and protein
analyses. Using qPCR, we showed that HIF-1a levels were
not increased after NT treatment (Figure 3A). However,
Western blot analysis revealed that HIF-1a protein accu-
mulates in the cytosol (30 minutes, P Z 0.0006; 6 hours,
P Z 0.0004; and P Z 0.0063 for 30 minutes versus 6
hours) (Figure 3, B and C). Importantly, this NT response
was reversed when cells were pretreated with the speciﬁc
NTR1 antagonist SR48692 (Figure 3, D and E). To furtherFigure 4 NT promotes HIF-1a protein activation, nuclear translocation, and
107 mol/L NT, and HIF-1a protein levels in isolated nuclei were assessed by
transfected with HRE-luciferase reporter plasmid, treated as indicated with 3  10
was assessed using the Dual Luciferase Reporter Assay System. D: NCM460-NTR1 ce
18hour pretreatment with 40  106 mol/L HIF-1a inhibitor PX-478, and the exp
separate experiments. Data are expressed as means  SEM (BeD). n Z 3. *P <
3410examine this response, we performed a pulse-chase enzyme-
linked immunosorbent assay for HIF-1a. In short,
NCM460-NTR1 cells were treated with 107 mol/L NT for
1 hour. Cells were then put in NT-free media, and cell ly-
sates were prepared at the indicated time points. Our results
showed that the increase in HIF-1a total levels signiﬁcantly
subsided as soon as 30 minutes after the removal of NT
from the culture medium (P Z 0.0351) (Figure 3F). These
results suggest that NT signaling inhibits HIF-1a degrada-
tion in NCM460-NTR1 cells in an NTR1-dependent
manner.
NT Signaling Promotes HIF-1a Nuclear Translocation
and Transcriptional Activity in NCM460-NTR1 Cells
We next investigated whether NT signaling promotes acti-
vation, nuclear translocation, and transcriptional activity of
HIF-1a. Western blot analysis performed on isolated nuclei
and cytoplasmic cell fractions in NCM460-NTR1 cells
incubated with NT revealed that NT promotes nucleartranscriptional activity. NCM460-NTR1 cells were treated as indicated with
WB analysis (A) and band densitometry (B). C: NCM460-NTR1 cells were
6 DGK inhibitor II and/or 107 mol/L NT (6 hours), and luciferase activity
lls were treated as indicated with 107 mol/L NT (6 hours), with or without
ression of VEGFa was assessed by qPCR. Results are representative of three
0.05 and **P < 0.01 (Student’s t-test).
ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Human intestinal microvascular-
endothelial cells (HIMECs) were subjected to
Matrigel tube formation assay in coculture with
NCM460-NTR1 cells and treated as indicated with
107 mol/L NT and 7  107 mol/L VEGFa inhib-
itor CBO-P11. Representative microphotographs of
randomly selected ﬁelds (A) were used to calculate
total tube length per area unit (pixel/pixel2) using
ImageJ software (B and C). D: Negative control
(adiponectin) and NTR1 mRNA levels were assessed
by qPCR. Results are representative of four sepa-
rate experiments. Data are expressed as means 
SEM (BeD). n Z 3. ***P < 0.001 (Student’s t-
test). Original magniﬁcation, 10 (A).
NTeHIF-1aeVEGFa in Colonic Inﬂammationtranslocation of HIF-1a (Figure 4, A and B). We next
assessed transcriptional activity of HIF-1 using an HRE-
luciferase reporter plasmid. NCM460-NTR1 cells were
cotransfected with HRE-luciferase and TK-Renilla reporter
plasmids, and 48 hours post transfection, cells were treated
with 107 mol/L NT or vehicle for 6 hours. We found that
luciferase activity was signiﬁcantly increased after 6 hours
of NT treatment (PZ 0.0085) (Figure 4C). Previous reports
indicated that hypoxia results in the accumulation of the
intracellular phosphatidic acid levels through the action of
DGK, whereas the pharmacological inhibition of DGK
prevents HIF-1edependent transcription.29,30 We found that
pretreatment of cells with 3  106 mol/L DGK inhibitor II
(30 minutes) signiﬁcantly attenuated HIF-1aeinduced
luciferase activity in response to NT (P Z 0.0356),
indicating that NT/NTR1 signaling promotes HIF-1a sta-
bilization and subsequent transcriptional activity in a DGK-
dependent manner (Figure 4C). To link NT-dependent
VEGFa expression to HIF-1a transcriptional activity, we
pretreated NCM460-NTR1 cells with the HIF-1a inhibitor
PX-478. Our results show that pharmacological inhibition of
HIF-1a diminished NT-dependent VEGFa expression
(PZ 0.0257) (Figure 4D). Thus, NTR1 activation results in
stabilization/activation, nuclear translocation, and tran-
scriptional activity of HIF-1a, leading to increased VEGF
expression in a HIF-1aedependent manner.
NT Signaling Is Pro-Angiogenic
We ﬁnally tested whether the NT-dependent induction of
VEGFa expression in NCM460-NTR1 cells promotes
angiogenesis in vitro by measuring tube formation of
HIMECs. We ﬁrst measured NTR1 mRNA and found that
HIMECs express detectable levels of NTR1 (Figure 5D).The American Journal of Pathology - ajp.amjpathol.orgHowever, direct exposure of HIMECs to 107 mol/L NT (6
hours) did not result in increased tube formation when these
cells were cultured alone on Matrigel (Figure 5B), whereas
exposure of the same cells to basic ﬁbroblast growth factor
resulted in increased tube formation serving as a positive
control (data not shown). In contrast, NT administration to
HIMECs cocultured with NCM460-NTR1 cells showed a
signiﬁcant increase in tube formation compared with
HIMECs exposed to NT or HIMECs co-cultured with
NCM460-NTR1 cells in the absence of NT exposure
(P < 0.0001) (Figure 5, A and B). Importantly, with the
exposure of HIMEC/NCM460-NTR1 coculture to 107
mol/L NT (6 hours) in the presence of 7  107 mol/L
VEGFa inhibitor CBO-P11, this effect was reversed
(P < 0.0001) (Figure 5, A and C). These results indicate that
NT increases angiogenesis in HIMECs by promoting
VEGFa expression in intestinal epithelial cells.
Discussion
Previous studies have indicated that the expression of the
neuropeptide NT and its high-afﬁnity receptor, NTR1, is
upregulated in the colonic mucosa of animal models of in-
testinal inﬂammation and in colon tissue samples from IBD
patients.2,3,7 We and others also reported that NT/NTR1
interactions promote acute intestinal inﬂammation of
different etiologies.2,3,7,42 Here we show that, compared with
WT, animals lacking NTR1 have signiﬁcantly lower intes-
tinal vascularity during colitis and that this effect is associ-
ated with reduced histological damage during acute,
TNBS-induced colitis. Our in vitro and in vivo evidence
also indicates that NT inﬂuences angiogenesis by stimulating
increased expression of the proangiogenic factor VEGFa in
colonocytes, which in turn stimulates tube formation by3411
Figure 6 Schematic representation of NT-NTR1 interactions in intesti-
nal epithelial cells leading to stimulation of intracellular signaling path-
ways during colitis and involving the transcription factor HIF-1a and VEGFa
and angiogenesis. NTR1 signaling activates HIF-1a transcriptional activity
via pathways that at least in part involve the activation of DGK, an enzyme
that catalyzes the conversion of diacylglycerol (DAG) to phosphatidic acid
(PA). The accumulation of PA leads to increased expression of HIF-1a,
promoting HIF-1aedependent pathways. Solid arrows represent direct
interactions. Dotted arrows represent indirect and hypothetical in-
teractions based on the available evidence.
Bakirtzi et alacting on HIMECs. We also present evidence that the
mechanism of VEGFa activation in colonocytes in response
to NT involves the activation of the transcription factor
HIF-1a. This HIF-1a NT response was rather speciﬁc since
NT failed to stabilize HIF-2 (data not shown), another VEGF
regulator in our experimental model. To our knowledge, this
is the ﬁrst report to indicate that NT regulates angiogenesis in
the inﬂamed intestine.
Our results indicate that NT does not increase tube for-
mation when exposed to HIMEC in vitro, despite the
presence of NTR1 in these cells. A low level of NTR1
expression may be involved in this lack of response. Pre-
vious results have indicated limited NT-induced activation
of human colonic NCM460 epithelial cells, which express
low levels of endogenous NTR1, but increased NTR1-
associated NF-kB and mitogen-activated protein kinase
signaling in NCM460 overexpressing this receptor.9,11,31
Similarly, there is increased expression of NTR1 in the
colonic mucosa in colitis and IBD compared with levels of
expression in normal colon.3,7,44 Previous studies have also
demonstrated the possibility that NT is involved in angio-
genic responses.27,28 The administration of an NT analogue
enhanced the migration of human umbilical vein endothelial
cells and induced neovascularization in the rat cornea
in vivo.27 Moreover, liver tumoreinitiating cells promoted
tumor angiogenesis in vivo via an NT/IL-8/CXCL1
signaling mechanism.28
We found that, in colonic epithelial cells, NT activates
HIF-1a by a mechanism that involves stabilization, nuclear
translocation, and transcriptional activity of HIF-1a. With
pretreatment of cells with DGK inhibitor II, the effect of NT/
NTR1 signaling on HIF-1a transcriptional activity was
partially reversed. This ﬁnding suggests that HIF-1a activa-
tion in our system is driven, at least in part, by previously
described molecular pathways involving the activation of a
G-proteinecoupled receptor and the subsequent intracellular
accumulation of phosphatidic acid, through the action of
DGK.29 Phosphatidic acid is a known oxygen sensor since it
accumulates during hypoxic conditions, leading to the acti-
vation of HIF-1a.30 With pretreatment of cells with the
speciﬁc HIF-1a inhibitor PX-478, VEGFa expression in
response to NT was substantially reduced, suggesting that
NT/NTR1-induced VEGFa expression involves, at least in
part, the activation of HIF-1a. This idea is consistent with
molecular evidence demonstrating that the promoter region
of VEGFa contains HREs.20,21 However, several other
transcription factors have binding sites on the VEGFa pro-
moter, including early growth response factor 1,45 a factor
activated by NTR1 signaling,10,46 whereas insulin-like
growth factor I receptor, which is transactivated by
NTR1,11 also regulates VEGFa transcription in human
colonic epithelial cells.47
During the clinical course of IBD, there is extensive tissue
injury caused by tissue edema, increased inﬂammatory cell
inﬁltrates, and increased angiogenesis, characteristic of the se-
vere metabolic shifts toward hypoxia, a process known to3412promote inﬂammation.12e14,48 Hypoxic conditions evident in
the colonic mucosa in colitis play a central role in the patho-
physiology of intestinal inﬂammation and IBD,49,50 in part by
regulating HIF-1a activation and inﬂammation-dependent
angiogenesis in colitis.49,50 Our evidence suggests that NT
can inﬂuence angiogenesis by promoting intestinal inﬂamma-
tion, which leads to hypoxia and HIF-1aedriven increased
angiogenesis, as well as by directly activating HIF-1a on in-
testinal epithelial cells, leading to increased VEGFa expression
and increased angiogenesis. Moreover, increased intestinal
angiogenesis, by itself, regulates the development and progress
of colitis,51 in part by facilitating the entry and distribution of
immune cells in the colonic mucosa.52
A key molecule in the induction of angiogenesis is
VEGFa, a paracrine growth factor involved in blood vessel
development as well as endothelial cell migration. Up-
regulated angiogenesis in the colon during active disease is
a key component of IBD driven to a large extent by VEGFa
expression,43,53 which represents a target for IBD treat-
ment.46 Accordingly, VEGFa expression is elevated in the
serum and colon of IBD patients.43,54 Our results show that
NT treatment of NCM460-NTR1 colonic epithelial cells was
associated with increased VEGFamRNA and protein levels,
whereas the in vivo increase in VEGFa expression after
TNBS treatment was lower in NTR1-KOmice. The source of
NT in this pathway includes neither human colonic epithelial
cells nor HIMECs since these cells do not express NTmRNA
(data not shown), excluding the possibility of an autocrine
signaling axis. Collectively, our results underline an impor-
tant role for NT in colitis-associated angiogenesis by an
NTR1-driven signaling network that involves HIF-
1eregulated VEGFa expression (Figure 6).ajp.amjpathol.org - The American Journal of Pathology
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